Accueil / Communiqués / Aldevron Announces Expansion of Antibody Development Facility

Aldevron Announces Expansion of Antibody Development Facility

Monday, March 4th 2019 at 12:20pm UTC

Increasing GENOVAC platform capacity and antibody development
services necessary to meet demand

SAN DIEGO–(BUSINESS WIRE)– Aldevron announced today from the floor of the Festival of Biologics in
San Diego, its expansion plans for its Freiburg, Germany facility. The
Freiburg location houses the GENOVAC antibody development platform and
became the second site for Aldevron in 2004.

Founding partner and CEO, Michael Chambers, cites the need for space and
capacity to support the company’s steady growth in providing world class
genetic immunization strategies with high-quality antibody generation to
customers across the globe as the major reason. “We have seen a marked
increase in demand, and this is an investment to better serve our
clients,” said Chambers. “We have been providing transformative antibody
development solutions for all target types for more than 15 years. By
expanding and enhancing our service offerings, we will be better able to
respond to the industry that is continuing to grow and provide the
solutions to some of the world’s biggest health challenges.”

The expansion plan adds approximately 4,300 square feet of laboratory
and production space to the current facility. The space provides
immediate room for growth in personnel and equipment for increased cell
culture, fusion, production and sequencing capacity while also providing
space for new services to be launched later in 2019.

About Aldevron

Aldevron Freiburg provides industry leading genetic immunization
strategies and monoclonal antibody development services in support of
the biotechnology industry at the former GENOVAC facility in Freiburg,
Germany.

Aldevron serves the biotechnology industry with custom production of
nucleic acids, proteins, and antibodies. Thousands of clients use
Aldevron-produced plasmids, RNA and gene editing enzymes for projects
ranging from discovery research to clinical trials to commercial
applications. These products are critical raw materials and key
components in commercially available drugs and medical devices. Aldevron
specializes in GMP manufacturing and is known for inventing the
GMP-SourceTM quality system. Company headquarters, plasmid
manufacturing, and GMP/GMPs facilities are in Fargo, North Dakota;
protein process development and production facility in Madison,
Wisconsin; and antibody development facility in Freiburg, Germany. To
learn more, visit www.aldevron.com.

Contacts

Ellen Shafer
Senior Director of Marketing and Communications
ellen.shafer@aldevron.com
701.219.0333

Source: Aldevron


Voir aussi

Poxel Reports Financial Results for Full Year 2018 and Provides Corporate Update

Thursday, March 21st 2019 at 4:45pm UTC Executed strategic agreement for Imeglimin with Roivant Sciences; …